|Bid||4.7600 x 2200|
|Ask||4.7400 x 1000|
|Day's Range||4.7100 - 4.9500|
|52 Week Range||3.2000 - 6.0000|
|Beta (5Y Monthly)||1.28|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 16, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.18|
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today unveiled positive results in a new long-acting interleukin (IL)-31 antibody program (KIND-039) that integrates the company's novel half-life extension technology. Results from the pharmacokinetic study of the molecule demonstrate that the fully caninized, high-affinity antibody has up to a three-fold longer half-life compared to tirnovetmab. This extended half-life is expected to allow for up to three-fold longer interval between dosing.
Kindred Bio (KIN) delivered earnings and revenue surprises of 15.15% and -0.94%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the fourth quarter and full year ended December 31, 2020 and provided updates on its programs. For the fourth quarter of 2020, KindredBio reported net revenues of $1.0 million and a net loss of $10.9 million, or $0.28 per share. For the full year 2020, net product revenues were $42.2 million and the net loss was $21.8 million, or $0.55 per share.